It's intuitive that a robust immune response to COVID-19 will result in a less severe, even asymptomatic infection. A new study puts some numbers to the term "robust."
As was the case with other "instant therapies" for COVID, convalescent plasma showed no utility whatsoever in a well-designed randomized controlled trial, something that should come as no surprise to anyone who has ever waded in the treacherous waters of drug discovery research. Another one bites the dust.
Are vaccines going to be adequately tested for safety and efficacy if Phase 3 clinical trials are not completed? Does convalescent plasma work to treat COVID? Is the COVID death toll inflated? We attempt to clarify these controversies.
For everything, there is a time and place. Emergency Use Authorizations by the FDA were necessary for COVID-19's recent past; they are not necessary and will be harmful when applied to a COVID-19 vaccine.
We have made amazing progress in the treatment of COVID-19. Two therapies – steroids and remdesivir – have already been shown to help. Those who benefit from these treatments owe thanks to patients who volunteered to participate in controlled clinical trials, and the physicians and pharmaceutical companies that lead them.